CASI Pharmaceuticals (CASIF) Operating Expenses (2022 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Operating Expenses came in at $16.5 million in Q4 2025, down 80.66% YoY from $85.4 million in Q4 2024, and up 245.08% on a QoQ basis from -$11.4 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Operating Expenses (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of Operating Expenses data on file, last reported at $16.5 million in Q4 2025.
- Quarterly Operating Expenses fell 80.66% year-over-year to $16.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$22.0 million (down 143.43% YoY) and the FY2025 annual result came in at $55.1 million, up 8.5% from the prior year.
- Operating Expenses improved to $16.5 million in Q4 2025, from -$11.4 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $85.4 million in Q4 2024 to a low of -$96.7 million in Q4 2022.
- A 4-year average of $783562.5 and a median of $8.9 million in 2023 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 1040.69% in 2024, down 221.62% in 2024.
- Tracing CASIF's Operating Expenses over 4 years: stood at -$96.7 million in 2022, then surged by 107.74% to $7.5 million in 2023, then surged by 1040.69% to $85.4 million in 2024, then plunged by 80.66% to $16.5 million in 2025.
- The last three Operating Expenses figures came in at $16.5 million (Q4 2025), -$11.4 million (Q3 2025), and -$13.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.71 Bn | 131.86 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.87 Bn | 78.87 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.40 Bn | 60.22 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.36 Bn | 54.22 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.91 Bn | 28.60 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.17 Bn | 9.78 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 541.02 Mn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.51 Mn |
| Sep 30, 2025 | -11.38 Mn |
| Jun 30, 2025 | -13.18 Mn |
| Mar 31, 2025 | -14.00 Mn |
| Dec 31, 2024 | 85.39 Mn |
| Sep 30, 2024 | -12.51 Mn |
| Jun 30, 2024 | -10.86 Mn |
| Mar 31, 2024 | -11.26 Mn |
| Dec 31, 2023 | 7.49 Mn |
| Sep 30, 2023 | 10.29 Mn |
| Jun 30, 2023 | 15.18 Mn |
| Mar 31, 2023 | 12.18 Mn |
| Dec 31, 2022 | -96.67 Mn |
| Sep 30, 2022 | 11.68 Mn |
| Jun 30, 2022 | 11.41 Mn |
| Mar 31, 2022 | 12.26 Mn |